# reload+after+2024-01-21 14:47:30.386646
address1§Ugland House
address2§South Church Street PO Box 309
city§George Town
zip§KY1-1104
country§Cayman Islands
website§https://www.theravance.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
fullTimeEmployees§111
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Rick E. Winningham M.B.A.', 'age': 63, 'title': 'Chairman & CEO', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 1775260, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Rhonda F. Farnum', 'age': 58, 'title': 'Chief Business Officer and Senior VP of Commercial & Medical Affairs', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 942806, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Richard A. Graham Ph.D.', 'age': 49, 'title': 'Strategic Advisor', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 1066599, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Aziz  Sawaf C.F.A.', 'age': 41, 'title': 'Senior VP & CFO', 'yearBorn': 1982, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Stuart  Knight', 'title': 'VP of IT&I & Chief Information Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Gail B. Cohen', 'title': 'Vice President of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brett A. Grimaud Esq.', 'age': 49, 'title': 'Senior VP, General Counsel & Secretary', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Stacy L. Pryce', 'title': 'Senior VP & Chief Strategy Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Aine  Miller Ph.D.', 'title': 'SVP of Dev., VP of Regu., Quality, Clinical Safety & Pharmacovigilance and Head of Ireland Office', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§5
compensationRisk§8
shareHolderRightsRisk§6
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.363
priceToSalesTrailing12Months§9.473916
currency§USD
dateShortInterest§1702598400
forwardEps§-0.61
pegRatio§-0.22
exchange§NGM
quoteType§EQUITY
shortName§Theravance Biopharma, Inc.
longName§Theravance Biopharma, Inc.
firstTradeDateEpochUtc§1400247000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f44e86c3-1b7b-3131-b6a5-9cdef50528ba
gmtOffSetMilliseconds§-18000000
targetHighPrice§20.0
targetLowPrice§10.0
targetMeanPrice§13.6
targetMedianPrice§14.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§5.955
grossMargins§0.12571
ebitdaMargins§-1.17502
trailingPegRatio§None
